ESR1 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC), i.e., breast cancer characterized by no immunohistochemical expression of the estrogen receptor (ER) or progesterone receptor (PR) and the absence of human epidermal growth factor receptor 2 (HER-2) overexpression, accounts for 15–20% of breast cancer cases [1].